Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Lori Drumm

Family Medicine Deer Lodge, MT Doctor of Osteopathy

NPI 1750393757 CMS profile 811519

1100 Hollenback Ln, Deer Lodge, MT 59722

Open in the dashboard

General payments

$1,774

107 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lori Drumm of Deer Lodge, MT is reported in the CMS Open Payments database as having received $1,774 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $65 4
2023 General $199 10
2022 General $682 40
2021 General $345 20
2020 General $243 16
2019 General $240 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lori Drumm
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Lori Drumm were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Lori Drumm Family Medicine median Middle half National median
2019 $240 $150 $41–$543 $163
2020 $243 $120 $32–$415 $114
2021 $345 $137 $35–$551 $132
2022 $682 $137 $37–$512 $149
2023 $199 $149 $42–$545 $160
2024 $65 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $398 24 payments
  2. Amgen Inc. $321 16 payments
  3. Novo Nordisk Inc $210 14 payments
  4. Teva Pharmaceuticals USA, Inc. $149 8 payments
  5. AstraZeneca Pharmaceuticals LP $131 10 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $79 4 payments
  7. Janssen Pharmaceuticals, Inc $73 5 payments
  8. GlaxoSmithKline, LLC. $62 3 payments
  9. Lilly USA, LLC $60 4 payments
  10. Novartis Pharmaceuticals Corporation $59 4 payments
  11. Other $231 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,774 107 payments
Products named General payments · program years 2019–2024
  1. QULIPTA $232 14 payments
  2. Ozempic $193 13 payments
  3. EVENITY $163 8 payments
  4. Repatha $158 8 payments
  5. RYBELSUS $152 10 payments
  6. Prolia $147 7 payments
  7. Otezla $140 7 payments
  8. UBRELVY $139 7 payments
  9. FARXIGA $92 7 payments
  10. AJOVY $81 4 payments
  11. Other $1,091 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 129 drugs

Part D claims

7,335

Median for Family Practice: 1,826

Drug cost

$507,210

Median for Family Practice: $120,094

Branded share of claims

21.6%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 98 $70,092
Ozempic Semaglutide Brand 50 $60,745
Eliquis Apixaban Brand 66 $43,233
Mounjaro Tirzepatide Brand 43 $42,120
Trulicity Dulaglutide Brand 36 $37,784
Farxiga Dapagliflozin Propanediol Brand 48 $34,184
Xarelto Rivaroxaban Brand 42 $33,209
Jardiance Empagliflozin Brand 34 $31,243
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 24 $16,545
Januvia Sitagliptin Phosphate Brand 16 $16,237

The 10 drugs with the highest cost, of 129 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $33
$33 — —
Korlym
  • Corcept Therapeutics $16
$16 — —
QULIPTA
  • AbbVie, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record